
Accordingly, clinicians look to base therapeutic decisions on comprehensive assessments of the different areas of involvement, including nails and the skin. The surge in therapeutic options, namely disease-modifying anti-rheumatic drugs—both biological and targeted synthetic—has elicited clinicians to use the full clinical picture of an individual patient. These excerpts are in accordance with the intelligence report, titled, "Psoriatic Arthritis Therapeutics Market—Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026," which has been of late added to Market Research Hub's (MRH) growing repository. Therapeutic alternatives for the treatment of psoriatic arthritis have surged drastically over the past decade which has led to markedly enhanced results for skin and joint disease. The introduction of cytokines such as IL-23, IL-17 and TNF fuel cellular responses which create cascading inflammation and these cytokines are subdued by specific biologic therapeutics, are emerging as therapeutic alternatives for psoriatic arthritis. Drugs inhibiting the phosphodiesterase family of enzymes are now being perceived as a novel potential treatment for psoriatic arthritis. PDE4 and PDE4A are involved in in hydrolysis and the subsequent inactivation of cyclic nucleotides. Even though synthetic and biologic DMARDs are in existence to treat psoriatic arthritis, the disease remains phlegmatic to treatment. Ergo, efficacy of PDE4 makes it popular treatment alternative.